TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, CK-MDS can carry a wide range of chromosomal abnorm...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee
פורמט: Journal article
שפה:English
יצא לאור: Springer Nature 2019

פריטים דומים

פריטים דומים